KEYTRUDA® is indicated for:
- Adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.
- Adjuvant treatment of adult patients with Stage III melanoma with lymph node involvement who have undergone complete resection.
- Treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.
- Treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®*) for cutaneous melanoma2
Stage III
Pembrolizumab is recommended as an adjuvant therapy option for Stage III cutaneous melanoma with clinically positive node(s).
Stage IV
Pembrolizumab is recommended as a preferred initial systemic therapy option for stage IV/metastatic cutaneous melanoma.
Please see the guidelines for complete recommendations.
References:
- 1. Merck Canada Inc. KEYTRUDA®Product Monograph. April 19, 2023.
- 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Melanoma Cancer, version 2. 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
CA-OOC-00027